# US 2025/0367184 A1 · Cyp11a1 inhibitor for use in the treatment of prostate cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367184 A1
- Document ID: US20250367184A1
- Status: Published application
- Kind: A1
- Application number: 18/696,317
- Filed: 2022-09-27
- Published: 2025-12-04
- Earliest claimed: 2021-09-28
- Applicants: Orion Corporation
- Inventors: Tarja IKONEN; Annamari VUORELA
- Web page: https://patentgrep.com/patent/US20250367184A1

## CPC

- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4166: having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention relates to the use of an activating AR gene alteration as a biomarker for identifying prostate cancer patients who have a higher probability to be responsive to the treatment with a CYP11A1 inhibitor. The invention also relates to a method for treating prostate cancer comprising a) obtaining or having obtained a sample from the patient; b) assaying or having assayed a sample to determine whether the patient has an activating AR gene alteration and c) if the patient has an activating AR gene alteration, treating the patient with a therapeutically effective amount of a CYP11A1 inhibitor.

## Claims

### Claim 1

A method for the treatment of prostate cancer in a patient having an activating androgen receptor (AR) gene alteration comprising administration to said patient a therapeutically effective amount of a CYP11A1 inhibitor.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the CYP11A1 inhibitor is a compound of formula (I) or a pharmaceutically acceptable salt thereof
wherein R1 is hydrogen or —CF3.

### Claim 3 (depends on 2)

The method according to claim 2, wherein R1 is hydrogen.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the patient having an activating AR gene alteration has a higher probability to be responsive to the treatment than the patient who does not have an activating AR gene alteration.

### Claim 5 (depends on 3)

The method according to claim 3, wherein the activating AR gene alteration is an AR gene amplification.

### Claim 6 (depends on 3)

The method according to claim 3, wherein the activating AR gene alteration is an activating AR-LBD mutation.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the activating AR-LBD mutation is an activating AR-LBD point mutation.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the patient has one or more of the activating AR-LBD point mutations selected from the group consisting of Q671R, I673T, L702H, V716M, V716L, K718E, R727L, V731M, W742L, W742C, A749T, A749V, M750I, G751S, V758A, S783N, Q799E, R847G, E873Q, H875Y, H875Q, F877L, T878A, T878S, D880E, L882I, S889G, D891N, D891H, D891Y, E894K, M896T, M896V, A897T, E898G, K911R, T919S and Q920R.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the patient has one or more of the activating AR-LBD point mutations selected from the group consisting of L702H, V716M, V716L, W742L, W742C, H875Y, F877L, T878A, T878S, D891Y, M896T and M896V.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the patient has one or more of the activating AR-LBD point mutations selected from the group consisting of L702H, V716M, V716L, W742C, H875Y, F877L, T878A, D891Y and M896T.

### Claim 11 (depends on 3)

The method according to claim 3, wherein the patient has previously received therapy with an androgen receptor antagonist or a CYP17A1 inhibitor.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the patient has previously received therapy with enzalutamide or abiraterone acetate or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 3)

The method according to claim 3, wherein the patient is resistant to androgen receptor antagonist therapy or a CYP17A1 inhibitor therapy.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the patient is resistant to treatment with enzalutamide or abiraterone acetate or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 3)

The method according to claim 3, wherein the prostate cancer to be treated is castration resistant prostate cancer (CRPC).

### Claim 16 (depends on 15)

The method according to claim 15, wherein the prostate cancer to be treated is metastatic castration resistant prostate cancer (mCRPC).

### Claim 17

A method for treating prostate cancer in a patient comprising
a) obtaining or having obtained a sample from the patient;
b) assaying or having assayed the sample to determine whether the patient has an activating AR gene alteration; and
c) if the patient has an activating AR gene alteration, treating the patient with a therapeutically effective amount of a CYP11A1 inhibitor.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the CYP11A1 inhibitor is a compound of formula (I) or a pharmaceutically acceptable salt thereof
wherein R1 is hydrogen or —CF3.

### Claim 19 (depends on 18)

The method according to claim 18, wherein R1 is hydrogen.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the patient having an activating AR gene alteration has a higher probability to be responsive to the treatment than a patient who does not have an activating AR gene alteration.

### Claim 21 (depends on 19)

The method according to claim 19, wherein the activating AR gene alteration is an AR gene amplification.

### Claim 22 (depends on 19)

The method according to claim 19, wherein the activating AR gene alteration is an activating AR-LBD mutation.

### Claim 23 (depends on 19)

The method according to claim 19, wherein the sample comprises AR or a portion thereof from the patient.

### Claim 24 (depends on 19)

The method according to claim 19, wherein the sample comprises a polynucleotide encoding AR or a portion thereof from the patient.

### Claim 25 (depends on 24)

The method according to claim 24, comprising determining the sequence of the AR-LBD polynucleotide or a portion thereof from the patient.

### Claim 26 (depends on 24)

The method according to claim 24, comprising subjecting the sample to a gene panel assay targeting the AR-LBD region designed to hybrid-capture known AR-LBD alterations.

### Claim 27 (depends on 19)

The method according to claim 19, wherein the prostate cancer to be treated is castration resistant prostate cancer (CRPC).

### Claim 28 (depends on 27)

The method according to claim 27, wherein the prostate cancer to be treated is metastatic castration resistant prostate cancer (mCRPC).

### Claim 29 (depends on 19)

The method according to claim 19, wherein the prostate cancer to be treated is castration sensitive prostate cancer (CSPC).

### Claim 30 (depends on 29)

The method according to claim 29, wherein the prostate cancer to be treated is metastatic castration sensitive prostate cancer (mCSPC).

### Claim 31

A method of selecting a patient suffering from prostate cancer for the treatment with a CYP11A1 inhibitor comprising
a) assaying or having assayed the sample to determine whether the patient has an activating AR gene alteration; and
b) if the patient has an activating AR-LBD gene alteration, selecting the patient for the treatment with a CYP11A1 inhibitor.

### Claim 32 (depends on 31)

The method according to claim 31, wherein the CYP11A1 inhibitor is a compound of formula (I) or a pharmaceutically acceptable salt thereof
wherein R1 is hydrogen or —CF3.

### Claim 33 (depends on 32)

The method according to claim 32, wherein R1 is hydrogen.

### Claim 34 (depends on 31)

The method according to claim 31, wherein the patient having an activating AR gene alteration has a higher probability to be responsive to the treatment than a patient who does not have an activating AR gene alteration.

### Claim 35 (depends on 31)

The method according to claim 31, wherein the patient suffers from castration resistant prostate cancer (CRPC).

### Claim 36 (depends on 35)

The method according to claim 35, wherein the patient suffers from metastatic castration resistant prostate cancer (mCRPC).

### Claim 37 (depends on 31)

The method according to claim 31, wherein the patient suffers from castration sensitive prostate cancer (CSPC).

### Claim 38 (depends on 37)

The method according to claim 37, wherein the patient suffers from metastatic castration sensitive prostate cancer (mCSPC).

### Claim 39

A method for identifying a patient suffering from prostate cancer who is more likely to respond to a treatment comprising a CYP11A1 inhibitor, the method comprising assaying or having assayed a sample obtained from the patient to determine whether the patient has an activating AR gene alteration, wherein such alteration identifies the patient as being more likely to respond to the treatment.

### Claim 40 (depends on 39)

The method according to claim 39, wherein the CYP11A1 inhibitor is a compound of formula (I) or a pharmaceutically acceptable salt thereof
wherein R1 is hydrogen or —CF3.

### Claim 41 (depends on 40)

The method according to claim 40, wherein R1 is hydrogen.

### Claim at position 42

42-45. (canceled)

### Claim 46 (depends on 2)

The method according to claim 2, wherein the CYP11A1 inhibitor is a pharmaceutically acceptable salt of the compound of formula (I)
wherein R1 is hydrogen.

### Claim 47 (depends on 2)

The method according to claim 2, wherein the CYP11A1 inhibitor is a compound of formula (I)
wherein R1 is hydrogen.

### Claim 48 (depends on 2)

The method according to claim 2, wherein the CYP11A1 inhibitor is a pharmaceutically acceptable salt of the compound of formula (I)
wherein R1 is —CF3.

### Claim 49 (depends on 2)

The method according to claim 2, wherein the CYP11A1 inhibitor is a compound of formula (I)
wherein R1 is —CF3.

### Claim 50 (depends on 18)

The method according to claim 18, wherein the CYP11A1 inhibitor is a compound of formula (I)
wherein R1 is —CF3.

### Claim 51 (depends on 18)

The method according to claim 18, wherein the CYP11A1 inhibitor is a pharmaceutically acceptable salt of the compound of formula (I)
wherein R1 is —CF3.

### Claim 52 (depends on 18)

The method according to claim 18, wherein the CYP11A1 inhibitor is a pharmaceutically acceptable salt of the compound of formula (I)
wherein R1 is hydrogen.

### Claim 53 (depends on 18)

The method according to claim 18, wherein the CYP11A1 inhibitor is a compound of formula (I)
wherein R1 is hydrogen.
